Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 929 participants.
Also called NCT02738151
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 929 participants
- Sponsor
- Registry
-
NCT02738151 -
2015-005101-36
-
- Other papers using this trial's data
- More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Bulgaria, Croatia, Czechia, Denmark, France, Greece, Hungary, Israel, Italy, Romania, Serbia, Slovakia, Sweden, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02738151. Randomized; no masking; primary purpose treatment. Start 2016-05-19 (registry gives no type); primary completion 2017-08-15 (actual). Results posted on 2018-09-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
- Acronym
- BRIGHT
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Insulin glargine, 300U/mL
- Intervention (Drug)
- Insulin degludec, 100 U/mL
- Intervention (Drug)
- Non-insulin anti-diabetic treatment
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02738151- Content hash
c724851a4d77c407acd76152f9c2ef418e530516e41172ea4a9d142572b265ea